Posted: 28 Sep 2015 09:00 PM PDT
Diaz's consulting and lobbying firm, FP1 Strategies, it should be
noted, was working for "legitimate" pharmaceutical companies, who of
course are not in league with the manufacturers of illicit drugs. But
his clients nonetheless did not wish to lose sales of any kind by having
their products — Claritin-D, Allegra-D, and Zyrtec-D — revert from open
shelves to behind the pharmacist's counter. Those alarmed by the ease
with which pseudoephedrine can be extracted from these products want
them out of the reach of meth manufacturers.
No comments:
Post a Comment